98 related articles for article (PubMed ID: 11797416)
1. [Pharmacokinetic behavioral changes of methamphetamine in methamphetamine-sensitized animal model].
Kitaichi K; Morishita Y; Hasegawa T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2001 Nov; 21(5):133-44. PubMed ID: 11797416
[TBL] [Abstract][Full Text] [Related]
2. The role of organic cation transporter-3 in methamphetamine disposition and its behavioral response in rats.
Nakayama H; Kitaichi K; Ito Y; Hashimoto K; Takagi K; Yokoi T; Takagi K; Ozaki N; Yamamoto T; Hasegawa T
Brain Res; 2007 Dec; 1184():260-9. PubMed ID: 17988657
[TBL] [Abstract][Full Text] [Related]
3. Methamphetamine blood concentrations in human abusers: application to pharmacokinetic modeling.
Melega WP; Cho AK; Harvey D; Laćan G
Synapse; 2007 Apr; 61(4):216-20. PubMed ID: 17230548
[TBL] [Abstract][Full Text] [Related]
4. Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge.
O'Neil ML; Kuczenski R; Segal DS; Cho AK; Lacan G; Melega WP
Synapse; 2006 Nov; 60(6):465-73. PubMed ID: 16897726
[TBL] [Abstract][Full Text] [Related]
5. Ritanserin reverses repeated methamphetamine-induced behavioral and neurochemical sensitization in mice.
Ago Y; Nakamura S; Kajita N; Uda M; Hashimoto H; Baba A; Matsuda T
Synapse; 2007 Sep; 61(9):757-63. PubMed ID: 17568413
[TBL] [Abstract][Full Text] [Related]
6. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice.
Ago Y; Nakamura S; Uda M; Kajii Y; Abe M; Baba A; Matsuda T
Neuropharmacology; 2006 Sep; 51(4):914-22. PubMed ID: 16863654
[TBL] [Abstract][Full Text] [Related]
7. Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats.
Milesi-Hallé A; Hendrickson HP; Laurenzana EM; Gentry WB; Owens SM
Toxicol Appl Pharmacol; 2005 Dec; 209(3):203-13. PubMed ID: 15916788
[TBL] [Abstract][Full Text] [Related]
8. Methamphetamine-induced locomotor activity and behavioral sensitization: are dopamine d3 receptors involved?
Jones CD; Bartee JA; Leite-Browning ML; Blackshear MA
Cell Mol Biol (Noisy-le-grand); 2007 May; 53(4):15-22. PubMed ID: 17531156
[TBL] [Abstract][Full Text] [Related]
9. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse.
Cho AK; Melega WP; Kuczenski R; Segal DS
Synapse; 2001 Feb; 39(2):161-6. PubMed ID: 11180503
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetic properties of methamphetamine in rats with previous repeated exposure to methamphetamine: the differences between Long-Evans and Wistar rats.
Fujimoto Y; Kitaichi K; Nakayama H; Ito Y; Takagi K; Takagi K; Hasegawa T
Exp Anim; 2007 Apr; 56(2):119-29. PubMed ID: 17460357
[TBL] [Abstract][Full Text] [Related]
11. Methamphetamine-induced hyperactivity and behavioral sensitization in PACAP deficient mice.
Fujii H; Ishihama T; Ago Y; Shintani N; Kakuda M; Hashimoto H; Baba A; Matsuda T
Peptides; 2007 Sep; 28(9):1674-9. PubMed ID: 17658665
[TBL] [Abstract][Full Text] [Related]
12. Protein expression profile in the amygdala of rats with methamphetamine-induced behavioral sensitization.
Iwazaki T; McGregor IS; Matsumoto I
Neurosci Lett; 2008 Apr; 435(2):113-9. PubMed ID: 18346852
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting change in brain dynamics induced by methamphetamine: enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization.
Narita M; Miyatake M; Shibasaki M; Tsuda M; Koizumi S; Narita M; Yajima Y; Inoue K; Suzuki T
J Neurochem; 2005 Jun; 93(6):1383-92. PubMed ID: 15935054
[TBL] [Abstract][Full Text] [Related]
14. Protein expression profile in the striatum of rats with methamphetamine-induced behavioral sensitization.
Iwazaki T; McGregor IS; Matsumoto I
Proteomics; 2007 Apr; 7(7):1131-9. PubMed ID: 17351886
[TBL] [Abstract][Full Text] [Related]
15. Methamphetamine exposure during the preweanling period causes prolonged changes in dorsal striatal protein kinase A activity, dopamine D2-like binding sites, and dopamine content.
Crawford CA; Williams MT; Newman ER; McDougall SA; Vorhees CV
Synapse; 2003 Jun; 48(3):131-7. PubMed ID: 12645038
[TBL] [Abstract][Full Text] [Related]
16. Methamphetamine-induced sensitization includes a functional upregulation of ventral pallidal 5-HT2A/2C receptors.
Napier TC; Istre ED
Synapse; 2008 Jan; 62(1):14-21. PubMed ID: 17957734
[TBL] [Abstract][Full Text] [Related]
17. Persistence of tolerance to methamphetamine-induced monoamine deficits.
Danaceau JP; Deering CE; Day JE; Smeal SJ; Johnson-Davis KL; Fleckenstein AE; Wilkins DG
Eur J Pharmacol; 2007 Mar; 559(1):46-54. PubMed ID: 17239369
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis.
Ujike H; Sato M
Ann N Y Acad Sci; 2004 Oct; 1025():279-87. PubMed ID: 15542728
[TBL] [Abstract][Full Text] [Related]
19. [Differences in neuronal toxicity and its molecular mechanisms between methamphetamine and methylphenidate].
Narita M; Asato M; Shindo K; Kuzumaki N; Suzuki T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Jun; 29(3):115-20. PubMed ID: 19663261
[TBL] [Abstract][Full Text] [Related]
20. Neuronal dopamine transporter activity, density and methamphetamine inhibition are differentially altered in the nucleus accumbens and striatum with no changes in glycosylation in rats behaviorally sensitized to methamphetamine.
Bjorklund NL; Sorg BA; Schenk JO
Synapse; 2008 Oct; 62(10):736-45. PubMed ID: 18651643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
